Aligos Completes Phase 2 B-SUPREME Enrollment
SOUTH SAN FRANCISCO, Calif., July 13, 2026 Aligos Therapeutics announced the completion of patient enrollment in both parts of...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
SOUTH SAN FRANCISCO, Calif., July 13, 2026 Aligos Therapeutics announced the completion of patient enrollment in both parts of...
SOUTH SAN FRANCISCO, Calif., April 14, 2026 Aligos Therapeutics, Inc. has announced encouraging progress in its Phase 2 B-SUPREME...
